![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Monika Tomaszewska-Kiecana, Anna Dryja, Martin Ullmann, Corinne Petit-Frere, Andras Illes, Christos Dagres & Joëlle Monnet. (2023) Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults. Expert Review of Clinical Immunology 19:4, pages 447-455.
Read now
Read now
Andreas Schneider, Philipp Richard, Philippe Mueller, Christoph Jordi, Mary Yovanoff & Jakob Lange. (2021) User-Centric Approach to Specifying Technical Attributes of Drug Delivery Devices: Empirical Study of Autoinjector-Cap Removal Forces. Patient Preference and Adherence 15, pages 159-168.
Read now
Read now
David Bernstein, Ian D. Pavord, Kenneth R. Chapman, Richard Follows, Jane H. Bentley, Isabelle Pouliquen & Eric Bradford. (2020) Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. Journal of Asthma 57:9, pages 987-998.
Read now
Read now
Scott Fettner, Christopher Mela, Florian Wildenhahn, Monica Tavanti, Christine Wells, Wendy Douglass & Navita L. Mallalieu. (2019) Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector. Expert Opinion on Drug Delivery 16:5, pages 551-561.
Read now
Read now
Uwe Klaus Zettl, Michael Hecker, Orhan Aktas, Torsten Wagner & Paulus S. Rommer. (2018) Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge. Expert Review of Clinical Immunology 14:2, pages 137-153.
Read now
Read now
Sibyl Wray, Brooke Hayward, Fernando Dangond & Barry Singer. (2018) Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study. Expert Opinion on Drug Delivery 15:2, pages 127-135.
Read now
Read now
Zhaoyang Li & Rachael Easton. (2018) Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. mAbs 10:1, pages 18-33.
Read now
Read now
V Limmroth, J Reischl, B Mann, X Morosov, A Kokoschka, I Weller & T Schreiner. (2017) Autoinjector preference among patients with multiple sclerosis: results from a national survey. Patient Preference and Adherence 11, pages 1325-1334.
Read now
Read now
Damiano Paolicelli, Eleonora Cocco, Valentina Di Lecce, Vita Direnzo, Lucia Moiola, Roberta Lanzillo, Paola Perini, Simona Malucchi, Giovanna Borriello, Emilio Portaccio, Valentina Panetta, Giuseppe Fenu, Francesca Sangalli, Laura Cacciaguerra & Maria Trojano. (2016) Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study. Expert Opinion on Drug Delivery 13:6, pages 799-805.
Read now
Read now
Ivonne Weller, Anna Saake, Thomas Schreiner, Julika Vogelreuter & Nicolas Petroff. (2015) Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Preference and Adherence 9, pages 951-959.
Read now
Read now
Antonios Bayas, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda & Kurt Marhardt. (2015) Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery 12:8, pages 1239-1250.
Read now
Read now
Articles from other publishers (7)
Herbert Schreiber, Joachim Hipp, Fabian Roßnagel & Christiane Moritz. (2023) Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing–remitting multiple sclerosis patients. Neurodegenerative Disease Management.
Crossref
Crossref
Marco Peresson, Salvatore Cottone, Vincenzo Brescia Morra, Giuseppe Salemi, Antonio Gallo, Paola Valentino & Luca Prosperini. (2022) Off-Adherence Keeping (OAK) observational study: intentional off-adherence immunomodulatory multiple sclerosis treatment. Neurodegenerative Disease Management 12:5, pages 241-251.
Crossref
Crossref
Christof Maucksch, Peer M. Aries, Silke Zinke & Ulf Müller-Ladner. (2020) Patient Satisfaction with the Etanercept Biosimilar SB4 Device, Among Rheumatoid Arthritis and Spondyloarthropathy Patients - A German Observational Study. The Open Rheumatology Journal 14:1, pages 7-14.
Crossref
Crossref
Chiara Zecca, Zbyšek Pavelek, Kateřina Přikrylová, Mascia Ghielmetti, Andreas Beeler & Claudio Gobbi. (2019) Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study. Multiple Sclerosis and Related Disorders 30, pages 104-109.
Crossref
Crossref
Jovana Ivanović, Tatjana Pekmezović & Jelena Drulović. (2019) Interferon beta: Medication which started the revolution in the treatment of multiple sclerosis. Medicinski podmladak 70:1, pages 53-57.
Crossref
Crossref
Spyros N. Deftereos, Evangelos Koutlas, Efrosini Koutsouraki, Athanassios Kyritsis, Panagiotis Papathanassopoulos, Nikolaos Fakas, Vaia Tsimourtou, Nikolaos Vlaikidis, Antonios Tavernarakis, Konstantinos Voumvourakis, Michalis Arvanitis, Dimitrios Sakellariou & Filippo DeLorenzo. (2018) Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study. BMC Neurology 18:1.
Crossref
Crossref
Marcello Moccia, Raffaele Palladino, Antonio Carotenuto, Cinzia Valeria Russo, Maria Triassi, Roberta Lanzillo & Vincenzo Brescia Morra. (2016) Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders 10, pages 90-96.
Crossref
Crossref